Israel’s Tarsius (see here) reported positive results in a study of its TRS01 treatment of Active Anterior Non-Infectious Uveitis – an inflammatory eye disease. It shows promise for saving the eyesight of patients with uveitic glaucoma, which has no current approved treatment.

https://tarsiuspharma.com/2020/10/08/october-5-2020/